Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.BiPar Sciences has demonstrated that one of its second-generation products inhibited pancreatic cancer cell growth in vitro and in vivo, both alone and in combination with oxaliplatin.
Subscribe to our email newsletter
The second-generation product, BSI-401, is BiPar’s new class of cancer therapies known as poly-ADP-ribose polymerase inhibitors.
In animals with orthotopic human pancreatic tumors, BSI-401 significantly reduced tumor burden and extended survival. In addition, a synergistic effect was seen with BSI-401 in combination with oxaliplatin.
BiPar’s novel, proprietary PARP (poly-ADP-ribose polymerase) inhibitors are the first of a new generation of drug candidates that show promising activity and a favorable toxicity profile. BiPar’s lead PARP inhibitor, BSI-201, is set to enter a series of Phase Ib and Phase II trials in major cancers by the end of 2007.
James Abbruzzese, professor of gastrointestinal medical oncology and associate medical director of the gastrointestinal center at the University of Texas, Anderson Cancer Center, said: “These results demonstrate the potential of BSI-401 to treat one of the most deadly and difficult-to-treat cancers. Because of PARP’s role in DNA repair, inhibitors of the protein may make tumors more sensitive to oxaliplatin, which induces breaks in DNA strands, and could also be powerful enough to act as a targeted monotherapy.”